
|Videos|January 19, 2023
Efficacy and Safety of JAK inhibitors for AD
Author(s)Brett King, MD, PhD, Alexandra K. Golant, MD
Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
2
New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement
3
Dermatology Times Spot Test: July 19, 2026
4
Social Media Mythbusters: The Summer Skin Care "Shutdown"
5
















